Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1)

Trial Profile

Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs ALLOD 2 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms ANODYNE1
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 29 Oct 2017 Planned number of patients changed from 150 to 120.
    • 12 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
    • 12 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top